Skip to main content
SpringerLink
Log in

Metastasiertes kastrationsresistentes Prostatakarzinom

Phase-III-Studie zu Olaparib plus Abirateron als Erstlinientherapie

  • Medizin aktuell
  • Published:
Uro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Author information

Authors and Affiliations

  1. MeckEvidence - Dienstleistungen für medizinische, Seestr. 11, 17252, Schwarz, Germany

    Heidrun Rexer

Authors
  1. Heidrun Rexer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rexer, H. Phase-III-Studie zu Olaparib plus Abirateron als Erstlinientherapie. Uro-News 24, 16–17 (2020). https://doi.org/10.1007/s00092-020-4049-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-020-4049-1

Search

Navigation